StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)

Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%

Castle Biosciences cash

Cash and short-term investments held at the end of each period.

Castle Biosciences's cash was $277.67M at Sep 30, 2026. For fiscal 2025 it was $299.51M, up 2.2% from the year before. The highest annual figure on record is $409.85M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$299.51M+2.2%
FY2024Dec 31, 2024$293.13M+20.6%
FY2023Dec 31, 2023$243.10M-6.0%
FY2022Dec 31, 2022$258.63M-21.5%
FY2021Dec 31, 2021$329.63M-19.6%
FY2020Dec 31, 2020$409.85M+314.6%
FY2019Dec 31, 2019$98.85M+2106.9%
FY2018Dec 31, 2018$4.48M+269.6%
FY2017Dec 31, 2017$1.21M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$277.67M-3.4%
Q2 FY2026Jun 30, 2026$266.81M-3.3%
Q1 FY2026Mar 31, 2026$261.69M-4.9%
Q4 FY2025Dec 31, 2025$299.51M+2.2%
Q3 FY2025Sep 30, 2025$287.54M+2.8%
Q2 FY2025Jun 30, 2025$275.93M+6.3%
Q1 FY2025Mar 31, 2025$275.15M+15.0%
Q4 FY2024Dec 31, 2024$293.13M+20.6%
Q3 FY2024Sep 30, 2024$279.79M+21.8%
Q2 FY2024Jun 30, 2024$259.69M+15.2%
Q1 FY2024Mar 31, 2024$239.21M+3.1%
Q4 FY2023Dec 31, 2023$243.10M-6.0%
Q3 FY2023Sep 30, 2023$229.75M-13.6%
Q2 FY2023Jun 30, 2023$225.51M-17.4%
Q1 FY2023Mar 31, 2023$232.06M-24.9%
Q4 FY2022Dec 31, 2022$258.63M-21.5%
Q3 FY2022Sep 30, 2022$265.98M-26.8%
Q2 FY2022Jun 30, 2022$273.17M-25.8%
Q1 FY2022Mar 31, 2022$309.02M-24.1%
Q4 FY2021Dec 31, 2021$329.63M-19.6%
Q3 FY2021Sep 30, 2021$363.18M+98.4%
Q2 FY2021Jun 30, 2021$368.34M+104.9%
Q1 FY2021Mar 31, 2021$406.98M+312.5%
Q4 FY2020Dec 31, 2020$409.85M+314.6%
Q3 FY2020Sep 30, 2020$183.05M+93.8%
Q2 FY2020Jun 30, 2020$179.76M+929.1%
Q1 FY2020Mar 31, 2020$98.65M+507.8%
Q4 FY2019Dec 31, 2019$98.85M+2106.9%
Q3 FY2019Sep 30, 2019$94.48M+2783.6%
Q2 FY2019Jun 30, 2019$17.47M+235.6%
Q1 FY2019Mar 31, 2019$16.23M+1239.1%
Q4 FY2018Dec 31, 2018$4.48M–
Q3 FY2018Sep 30, 2018$3.28M–
Q2 FY2018Jun 30, 2018$5.21M–
Q4 FY2017Dec 31, 2017$1.21M–

More Castle Biosciences figures

See a number that looks wrong?